Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$164.99 USD

164.99
4,422,792

-2.37 (-1.42%)

Updated Sep 5, 2024 04:00 PM ET

After-Market: $164.96 -0.03 (-0.02%) 5:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Sheraz Mian headshot

Top Analyst Reports for Novo Nordisk, Bank of America & Netflix

Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Bank of America Corporation (BAC) and Netflix, Inc. (NFLX).

J&J (JNJ) Seeks Expanded Use of Lung Cancer Drug Rybrevant

J&J's (JNJ) sBLA seeks label expansion for Rybrevant plus chemotherapy to treat patients with EGFR-mutated NSCLC whose disease progressed on or after treatment with AstraZeneca's Tagrisso (osimertinib).

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

Sector ETF report for IYH

Andrew Rocco headshot

13F Rundown: Tepper, Buffett, Druckenmiller

Stock Strategist Andrew Rocco divulges valuable insights from the world's best and brightest investors.

Should Vanguard High Dividend Yield ETF (VYM) Be on Your Investing Radar?

Style Box ETF report for VYM

Johnson & Johnson (JNJ) Down 2.6% Since Last Earnings Report: Can It Rebound?

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, J&J and AbbVie

Eli Lilly, Novo Nordisk, J&J and AbbVie are part of the Zacks Industry Outlook article.

Kinjel Shah headshot

4 Large Drug Stocks Likely to Sail Through Industry Woes

Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), J&J (JNJ) and AbbVie (ABBV) are worth retaining in your portfolio.

Should You Invest in the Vanguard Health Care ETF (VHT)?

Sector ETF report for VHT

Bayer's (BAYRY) Q3 Earnings and Revenues Miss Estimates

Bayer (BAYRY) reports weaker-than-expected third-quarter 2023 results. Management maintains its 2023 outlook.

Halozyme (HALO) Q3 Earnings Top Estimates, Revenues Lag

Halozyme's (HALO) third-quarter earnings beat estimates, while revenues miss the same. The company maintains revenue guidance for full-year 2023.

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

GSK Beats on Q3 Earnings and Sales, Raises 2023 Guidance

GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales on the back of strong RSV vaccine sales.

AbbVie (ABBV) Q3 Earnings Beat, Shares Down Despite Raised View

AbbVie's (ABBV) third-quarter 2023 earnings and sales beat estimates. Though the company raised its EPS outlook for both 2023 and 2024, share price dives as some key drugs misses out on estimates.

Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?

Smart Beta ETF report for HDV

Alkermes (ALKS) Down Despite Q3 Earnings & Revenue Beat

Alkermes' (ALKS) earnings and revenues trump estimates in the third quarter of 2023. The company reiterates total revenue guidance for full-year 2023. Shares fall.

Ahan Chakraborty headshot

Drug, Biotech Stocks' Q3 Earnings Due on Oct 26: BMY, MRK, BPMC

Let's look at three biotech/drug companies, BMY, MRK and BPMC, slated to release quarterly results on Oct 26.

Charles River (CRL) Offers Access to Preclinical Cancer Research

Charles River (CRL) contributes to 84 percent of the FDA-approved cancer medicines and provides partners with 16 oncology prospects.

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ Posts Upbeat Q3 Earnings, PFE, NVO Revise 2023 View

J&J (JNJ) reports strong third-quarter results. Merck's (MRK) new deal with Japan's Daiichi Sankyo to jointly develop the latter's three DXd ADC candidates.

Sweta Killa headshot

JNJ Beats Q3 Earnings Estimates, Raises View: ETFs in Focus

The world's biggest healthcare products maker continued with its long streak of earnings beat and lifted the full year outlook.

Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now?

Smart Beta ETF report for VALQ

J&J (JNJ) Beats Q3 Earnings & Sales Estimates Post Spin-Off

J&J (JNJ) beats estimates for third-quarter earnings and sales. It raises full-year sales and earnings guidance.

Retail Sales Increased More Than Expected

Retail Sales Increased More Than Expected